|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Natural history of cytomegalovirus infection in a series of patients diagnosed with moderate-severe ulcerative colitis显示文摘AIM:To evaluate the natural history of human cytomegalovirus(HCMV) infection in a series of 28 ulcerative colitis patients in whom the search for HCMV was positive.METHODS:A series of 85 patients with moderate-severe ulcerative colitis flare-up were evaluated for a HCMV search by performing a haematoxylin and eosin stain,immunohistochemical assay and nested polymerase chain reaction on rectal biopsies.Among 85 screened patients(19 of whom were steroid resistant/dependant),28 were positive for HCMV;after remission the patients were followed up clinically and histologically.RESULTS:Among the 22 patients with complete followup,in 8(36%) patients HCMV-DNA persisted in the intestinal specimens.Among the HCMV positive patients,4(50%) experienced at least one moderate-severe flare-up of colitis without evidence of peripheral HCMV.Among the 14 HCMV negative patients,3 with pouches developed pouchitis and 5 out of 11(45%) experienced a colitis flare-up.CONCLUSION:Our preliminary results suggest that HCMV may remain in the colon after an acute colitis flareup despite remission;it seems that the virus is not responsible for the disease relapse. | Valeria Criscuoli Maria Rosa Rizzuto Luigi Montalbano Elena Gallo Mario Cottone | 2011 | World Journal of Gastroenterology2011，17，5： | 20 |
| 2 | Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate显示文摘Alterations of intestinal microflora may significantly contribute to the pathogenesis of different inflammatory and autoimmune disorders. There is emerging interest on the role of selective modulation of microflora in inducing benefits in inflammatory intestinal disorders, by as probiotics, prebiotics, synbiotics, antibiotics, and fecal microbiota transplantation(FMT). To summarize recent evidences on microflora modulation in main intestinal inflammatory disorders, Pub Med was searched using terms microbiota, intestinal flora, probiotics, prebiotics, fecal transplantation. More than three hundred articles published up to 2015 were selected and reviewed. Randomized placebo-controlled trials and meta-analysis were firstly included, mainly for probiotics. A meta-analysis was not performed because of the heterogeneity of these studies. Most of relevant data derived from studies on probiotics, reporting some efficacy in ulcerative colitis and in pouchitis, while disappointing results are available for Crohn's disease. Probiotic supplementation may significantly reduce rates of rotavirus diarrhea. Efficacy of probiotics in NSAID enteropathy and irritable bowel syndrome is still controversial. Finally, FMT has been recently recognized as an efficacious treatment for recurrent Clostridium difficile infection. Modulation of intestinal flora represents a very interesting therapeutic target, although it still deserves some doubts and limitations. Future studies should be encouraged to provide new understanding about its therapeutical role. | Antonella Gallo Giovanna Passaro Antonio Gasbarrini Raffaele Landolfi Massimo Montalto | 2016 | World Journal of Gastroenterology2016，22，32： | 19 |
| 3 | Updates on esophageal and gastric cancers显示文摘食道、胃的癌症普通、致命。病人现在的大多数经常因此在疾病前进和幸存以后是差的。由于在发病率的人口统计的可变性和最近的变化,许多强调被放在为食道、胃的癌症学习风险因素上。与增加这些疾病的理解,然而,低幸存率坚持并且继续的集中的研究是必要的优化治疗计划。这篇评论文章在演变传染病学讨论更改,临床的表示,风险因素,并且诊断并且食道、胃的癌症的治疗形式。 | Amy Gallo Charles Cha | 2006 | World Journal of Gastroenterology2006，12，20： | 18 |
| 4 | Evidence-based medicine and precision medicine:complementary approaches to clinical decision-making显示文摘Evidence-based medicine is widely promoted for decision-making in health care and is associated with improved patient outcomes.Critics have suggested that evidence-based medicine focuses primarily on groups of patients rather than individuals,but often fail to consider subgroup analyses,N-of-1 trials,and the incorporation of patient values and preferences.Precision medicine has been promoted as an approach to individualize diagnosis and treatment of diseases through genetic,biomarker,phenotypic,and psychosocial characteristics.However,there are often high costs associated with personalized medicine,and high-quality evidence is lacking for effectiveness in many applications.For the potential of personalized medicine to be realized,it must adhere to the principles of evidencebased medicine:(1)evidence in isolation is not sufficient to make clinical decisions—patient’s values and preferences as well as resource implications must be considered,and(2)there is a hierarchy of evidence to guide clinical decision-making and studies at lower risk of bias are likely to provide more trustworthy findings. | Ngai Chow Lucas Gallo Jason W.Busse | 2018 | Precision Clinical Medicine2018，1，2： | 10 |
| 5 | NG2 Cell Response in the CNP-EGFP Mouse After Contusive Spinal Cord Injury显示文摘成年动物中枢神经系统中的NG2细胞具有异质性。脊髓损伤(SCI)后,具有少突胶质前体细胞(OPCs)功能的NG2细胞亚型如何产生反应性变化及对其正常的发育过程有何影响目前还不清楚。本文采用少突胶质细胞系细胞表达EGFP的CNP-EGFP小鼠,研究正常和SCI后的NG2细胞的特征。在正常小鼠的白质中,对EGFP+NG2+双极细胞和EGFPnegNG2+多极细胞进行鉴别。SCI后,白质损伤边缘区中的EGFP+NG2+细胞3 d增殖达高峰,损伤中心区的EGFPnegNG2+细胞增殖在损伤后7 d达高峰。损伤后EGFP+NG2+细胞的Olig2、Sox10、Sox17等转录因子、基本的膜电生理参数以及钾电流表型均与发育过程增殖的OPCs一致。EGFPnegNG2+细胞不表达少突胶质发生中的转录因子。EGFP+CC1+少突胶质细胞6周时包含在EGFP+NG2+细胞增殖峰时表达BrdU的细胞。EGFPnegCC1+少突胶质细胞未被观察到。神经胶质生长因子2和成纤维细胞生长因子2处理促进少突胶质发生,提高EGFPnegNG2+细胞数量。因此,通过EGFP和转录因子表达,时空增殖类型及对生长因子的反应,两种类型的NG2+细胞对SCI刺激发生反应。SCI后EGFP+NG2+细胞经受细胞和生理变化特征,与在早期出生后的少突胶质发生过程中NG2+细胞中的变化类似。 | JUDITH M LYTLE RAMESH CHITTAJALLU JEAN R WRATHALL VITTORIO GALLO | 2009 | 神经损伤与功能重建2009，4，1： | 7 |
| 6 | Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study显示文摘AIM To treated with electrochemotherapy(ECT) a prospective case series of patients with liver cirrhosis and Vp3-Vp4- portal vein tumor thrombus(PVTT) from hepatocellular carcinoma(HCC), in order to evaluate the feasibility, safety and efficacy of this new non thermal ablative technique in those patients. METHODS Six patients(5 males and 1 female), aged 61-85 years(mean age, 70 years), four in Child-Pugh A and two in Child-Pugh B class, entered our study series. All patients were studied with three-phase computed tomography(CT), contrast enhanced ultrasound(CEUS) and ultrasound-guided percutaneous biopsy of the thrombus before ECT. All patients underwent ECT treatment(Cliniporator Vitae?, IGEA Sp A, Carpi, Modena, Italy) of Vp3-Vp4 PVTT in a single session. At the end of the procedure a post-treatment biopsy of the thrombus was performed. Scheduled follow-up in all patients entailed: CEUS within 24 h after treatment; triphasic contrastenhanced CT and CEUS at 3 mo after treatment and every six months thereafter.RESULTS Post-treatment CEUS showed complete absence of enhancement of the treated thrombus in all cases. Post-treatment biopsy showed apoptosis and necrosis of tumor cells in all cases. The follow-up ranged from 9 to 20 mo(median, 14 mo). In 2 patients, the followup CT and CEUS demonstrated complete patency of the treated portal vein. Other 3 patients showed a persistent avascular non-tumoral shrinked thrombus at CEUS and CT during follow-up. No local recurrence was observed at follow-up CT and CEUS in 5/6 patients. One patient was lost to follow-up because of death from gastrointestinal hemorrage 5 wk after ECT. CONCLUSION In patients with cirrhosis, ECT seems effective and safe for curative treatment of Vp3-Vp4 PVTT from HCC. | Luciano Tarantino Giuseppina Busto Aurelio Nasto Raffaele Fristachi Luigi Cacace Maria Talamo Catello Accardo Sara Bortone Paolo Gallo Paolo Tarantino Riccardo Aurelio Nasto Matteo Nicola Dario Di Minno Pasquale Ambrosino | 2017 | World Journal of Gastroenterology2017，23，5： | 7 |
| 7 | Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis显示文摘Hepatitis C virus(HCV)is one of the main causes of liver disease worldwide,and alterations of glucose metabolism have reached pandemic proportions in western countries.However,the frequent coexistence between these two conditions is more than simply coincidental,since HCV can induce insulin resistance through several mechanisms.Indeed,the virus interferes with insulin signaling both directly and indirectly,inducing the production of pro-inflammatory cytokines.Furthermore,the entire viral life cycle has strict interconnections with lipid metabolism,and HCV is responsible for a'viral'steatosis which is frequently superimposed to a'metabolic'one.Several evidences suggest that HCV-induced metabolic disorders contribute both to the evolution of liver fibrosis and,likely,to the progression of the other disorders which are typically associated with altered metabolism,in particular atherosclerosis.In the present review,we will examine in depth the links between HCV infection and insulin resistance,liver steatosis and diabetes,and analyze the impact of these interactions on the progression of liver fibrosis and atherosclerosis.Special attention will be focused on the highly debated topic of the relationship between HCV infection and cardiovascular disease.The available clinical literature on this item will be broadly reviewed and all the mechanisms possibly implied will be discussed. | Umberto Vespasiani-Gentilucci Paolo Gallo Antonio De Vincentis Giovanni Galati Antonio Picardi | 2014 | World Journal of Gastroenterology2014，20，11： | 5 |
| 8 | Update on the treatment of focal segmental glomerulosclerosis in renal transplantation显示文摘Focal segmental glomerulosclerosis(FSGS) represents one of the most severe glomerular diseases, with frequent progression to end-stage renal disease and a high rate of recurrence in renal allografts(30%-50%). Recurrent FSGS portends a negative outcome, with the hazard ratio of graft failure being two-fold higher then that of other glomerulonephritis. Two patterns of clinical presentations are observed: Early recurrence, which is characterized by massive proteinuria within hours to days after implantation of the renal graft, and late recurrence, which occurs several months or years after the transplantation. Many clinical conditions have been recognized as risk factors for recurrence, including younger age, rapid progression of the disease to end-stage renal disease on native kidneys, and loss of previous renal allografts due to recurrence. However, much less is known about the incidence and risk factors of the so-called 'de novo ' type of FSGS, for which sufferers are transplanted patients without disease on native kidneys; but, rapid development of allograft failure is frequently observed. Management of both forms is challenging, and none of the approaches proposed to date have been demonstrated as consistently beneficial or effective. In the present review we report an update on the available therapeutic strategies for FSGS in renal transplantation within the context of a critical overview of the current literature. | Maria Messina Ester Gallo Alberto Mella Fabiola Pagani Luigi Biancone | 2016 | World Journal of Transplantation2016，6，1： | 5 |
| 9 | Thrombocytopenia in chronic liver disease:Physiopathology and new therapeutic strategies before invasive procedures显示文摘Chronic liver disease is characterized by several hematological derangements resulting in a complex and barely rebalanced haemostatic environment.Thrombocytopenia is the most common abnormality observed in these patients and recent advances have led to researchers focus the attention on the multifactorial origin of thrombocytopenia and on the key role of thrombopoietin(TPO)in its physiopathology.Severe thrombocytopenia(platelet count<50000/μL)complicates the management of patients with chronic liver disease by increasing the potential risk of bleeding for invasive procedures,which may be therefore delayed or canceled even if lifesaving.In the very last years,the development of new drugs which exceed the limits of the current standard of care(platelet transfusions,either immediately before or during the procedure)paves the way to a new scenario in the management of this population of patients.Novel agents,such as the TPOreceptor agonists avatrombopag and lusutrombopag,have been developed in order to increase platelet production as an alternative to platelet transfusions.These agents have demonstrated a good profile in terms of efficacy and safety and will hopefully allow reducing limitations and risks associated with platelet transfusion,without any delay in scheduled interventions.Altogether,it is expected that patients with chronic liver disease will be able to face invasive procedures with one more string in their bow. | Paolo Gallo Francesca Terracciani Giulia Di Pasquale Matteo Esposito Antonio Picardi Umberto Vespasiani-Gentilucci | 2022 | World Journal of Gastroenterology2022，28，30： | 5 |
| 10 | International NeuroAIDS: prospects of HIV-1 associated neurological com-plications显示文摘Neurological complications associated with HIV-1/AIDS are being recognized with a high frequency that parallels the increased number of AIDS cases. The early infiltration by HIV-1 into the nervous system can cause primary and/or secondary neurological complications. The most common neurocognitive disorder is AIDS Dementia Complex (ADC). In developing countries of Asia the three most opportunistic infections are tuberculosis (TB), cryptococcosis, and Pneumocystis carinii pneumonia. Therefore, it is expected that secondary neurological complications due to TB and cryptococcosis will be the most common cause of morbility and mortality in HIV-1/AIDS cases in China. Research of NeuroAIDS in China is necessary to understand the impact and the biology of HIV-1 in the nervous system. Future studies would include, the molecular epidemiology and the description of opportunistic infections associated to HIV-1; the neuropathological description of primary and secondary HIV-1 complications in different groups; the HIV-1 neurot- ropism and immune response studies for China’s unique HIV-1 strains and recombinant forms derived from the nervous system, including experimental models such as the use of transgenic rats; and the study of potential resistant virus, primarily when the anti-retroviral therapy (ART) has not full access in the brain. | J Roberto TRUJILLO Gilberto JARAMILLO-RANGEL Marta ORTEGA-MARTINEZ Augusto C PENALVA de OLIVEIRA Jose E VIDAL Joseph BRYANT Robert C GALLO | 2005 | Cell Research2005，15，11： | 4 |
| 11 | Hepatitis C treatment in the elderly:New possibilities and controversies towards interferon-free regimens显示文摘Due to the progressive aging of the hepatitis C virus(HCV) population which have acquired the infection during its maximum spread after the Second World War, the management of the elderly HCV-infected patient is emerging as a hot topic. Unfortunately, although it is recognized that the progression of HCV-related liver disease gets faster with aging, and that even extrahepatic manifestations of HCV infection are probably worse in the elderly, till now, treatment attempts in this population have been significantly limited by the wellknown contraindications and side effects of interferon(IFN). The arrival of several new anti-HCV drugs, and the possibility to combine them in safe and effective anti-viral regimens, is relighting the hope of a cure for many elderly patients who had been cut out of IFN-based treatments. However, although these new regimens will be certainly more manageable, it should be underscored that IFN-free doesn't mean free from any contraindication or side-effect. Moreover, one issue which promises to become central is that of the possible interactions between antiviral therapy and the multiple drugs frequently assumed by elderly patients because of comorbidities. In this review, we will revise the epidemiology pointing to HCV as an infection of the elderly, the evidences that HCV harms the health of the aged patient more than that of the young one, and the available experiences of HCV treatment in the elderly with the 'old' IFN-based regimens and with the newer drugs. We will conclude that the availability of IFNfree regimens should prompt us to change our mind and consider a significantly larger number of possible candidates among elderly patients, who would take significant advantage from viral eradication. Rather than the anagraphic age, drug-drug interactions and, mainly in case of economic restrictions, an evaluation of life expectancy dependent on liver disease with respect to that dependent on comorbidities, are likely to be the key issues guiding treatment indication in the next future. The sooner we will change our mind with respect to an a priori obstacle for anti-HCV treatment in the elderly, the sooner we will begin to spare many aged HCV patients from avoidable liver-related complications. | Umberto Vespasiani-Gentilucci Giovanni Galati Paolo Gallo Antonio De Vincentis Elisabetta Riva Antonio Picardi | 2015 | World Journal of Gastroenterology2015，21，24： | 4 |
| 12 | Effects of diabetic ketoacidosis in the respiratory system显示文摘Diabetes affects approximately 30 million persons in the United States. Diabetes ketoacidosis is one of the most serious and acute complications of diabetes. At the time of presentation and during treatment of diabetic ketoacidosis(DKA), several metabolic and electrolyte derangements can ultimately result in respiratory compromise. Most commonly, hypokalemia, hypomagnesemia and hypophosphatemia can eventually lead to respiratory muscles failure.Furthermore, tachypnea, hyperpnea and more severely, Kussmaul breathing pattern can develop. Also, hydrostatic and non-hydrostatic pulmonary edema can occur secondary to volume shifts into the extracellular space and secondary to increased permeability of the pulmonary capillaries. The presence of respiratory failure in patients with DKA is associated with higher morbidity and mortality. Being familiar with the causes of respiratory compromise in DKA, and how to treat them, may represent better outcomes for patients with DKA. | Alice Gallo de Moraes Salim Surani | 2019 | World Journal of Diabetes2019，10，1： | 4 |
| 13 | Rectal neuroendocrine tumors:Current advances in management,treatment,and surveillance显示文摘Rectal neuroendocrine neoplasms(r-NENs)are considered among the most frequent digestive NENs,together with small bowel NENs.Their incidence has increased over the past few years,and this is probably due to the widespread use of endoscopic screening for colorectal cancer and the advanced endoscopic procedures available nowadays.According to the current European Neuroendocrine Tumor Society(ENETS)guidelines,well-differentiated r-NENs smaller than 10 mm should be endoscopically removed in view of their low risk of local and distant invasion.R-NENs larger than 20 mm are candidates for surgical resection because of their high risk of distant spreading and the involvement of the muscularis propria.There is an area of uncertainty regarding tumors between 10 and 20 mm,in which the metastatic risk is intermediate and the endoscopic treatment can be challenging.Once removed,the indications for surveillance are scarce and poorly codified by international guidelines,therefore in this paper,a possible algorithm is proposed. | Camilla Gallo Roberta Elisa Rossi Federica Cavalcoli Federico Barbaro Ivo Boškoski Pietro Invernizzi Sara Massironi | 2022 | World Journal of Gastroenterology2022，28，11： | 4 |
| 14 | Resection of a rapid-growing 40-cm giant liver hemangioma显示文摘Hemangiomas are the most frequent benign tumors of the liver. Most hemangiomas are asymptomatic and therefore largely diagnosed only in routine screening tests. Usually they are small and require no specific treatment. In some situations they can reach great dimensions, causing some discomfort to the patient. Resection of liver hemangioma is indicated in cases of great dimension tumors causing symptoms such as pain, nausea or bloating caused by compression of adjacent organs. We report a case of a rare giant hemangioma with rapid growth in short time:a 50 year old female reported to our institution with a 40 cm giant liver hemangioma and then underwent a left hepatectomy. | Andreas JM Koszka Fabio G Ferreira Caio GG de Aquino Maurício A Ribeiro André S Gallo Elisa MC Aranzana Luiz A Szutan | 2010 | World Journal of Hepatology2010，2，7： | 3 |
| 15 | Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials显示文摘 | Massimo Di Maio Cesare Gridelli Ciro Gallo Frances Shepherd Franco Vito Piantedosi Silvio Cigolari Luigi Manzione Alfonso Illiano Santi Barbera Sergio Federico Robbiati Luciano Frontini Elena Piazza Giovanni Pietro Ianniello Enzo Veltri Federico Castiglio | 2005 | Lancet Oncology2005，，9： | 2 |
| 16 | Precision micro-mechanical components in single crystal diamond by deep reactive ion etching显示文摘The outstanding material properties of single crystal diamond have been at the origin of the long-standing interest in its exploitation for engineering of high-performance micro-and nanosystems.In particular,the extreme mechanical hardness,the highest elastic modulus of any bulk material,low density,and the promise for low friction have spurred interest most notably for micro-mechanical and MEMS applications.While reactive ion etching of diamond has been reported previously,precision structuring of freestanding micro-mechanical components in single crystal diamond by deep reactive ion etching has hitherto remained elusive,related to limitations in the etch processes,such as the need of thick hard masks,micromasking effects,and limited etch rates.In this work,we report on an optimized reactive ion etching process of single crystal diamond overcoming several of these shortcomings at the same time,and present a robust and reliable method to produce fully released micro-mechanical components in single crystal diamond.Using an optimized Al/SiO_(2) hard mask and a high-intensity oxygen plasma etch process,we obtain etch rates exceeding 30μm/h and hard mask selectivity better than 1:50.We demonstrate fully freestanding micro-mechanical components for mechanical watches made of pure single crystal diamond.The components with a thickness of 150μm are defined by lithography and deep reactive ion etching,and exhibit sidewall angles of 82°–93°with surface roughness better than 200 nm rms,demonstrating the potential of this powerful technique for precision microstructuring of single crystal diamond. | Adrien Toros Marcell Kiss Teodoro Graziosi Hamed Sattari Pascal Gallo Niels Quack | 2018 | Microsystems & Nanoengineering2018，4，1： | 2 |
| 17 | Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity显示文摘AIM: To investigate the toxicity and response of intensity-modulated radiotherapy schedule intensified with a simultaneous integrated boost in anal canal cancer.METHODS: From March 2009 to March 2014, we retrospectively analyzed 41 consecutive patients treated with intensity-modulated radiotherapy(IMRT) and concurrent chemotherapy for anal canal squamous cell carcinoma at our center. Radiotherapy was delivered via simultaneous integrated boost(SIB) technique by helical tomotherapy, and doses were adapted to two clinical target volumes according to the tumor-nodemetastasis(TNM) stage: 50.6 Gy and 41.4 Gy in 23 fractions in T1N0, 52.8 Gy and 43.2 Gy in 24 fractionsin T2N0, and 55 Gy and 45 Gy in 25 fractions in all patients with N positive and/or ≥ T3, respectively, to planning target volumes 1 and 2. The most common chemotherapy regimen was 5-fluorouracil and mitomycin-based. Human papilloma virus(HPV) p16 expression was performed by immunohistochemistry and evaluated in the majority of patients. Acute and late toxicity was scored according to CTCAe v 3.0 and RTOG scales.RESULTS: The median follow-up was 30 mo(range:12-71). Median age was 63 years(range 32-84). The stage of disease was: stage Ⅰ in 2 patients, stage Ⅱin 13 patients, stage ⅢA in 12 patients, and stage ⅢB in 14 patients, respectively. Two patients were known to be HIV positive(4.9%). HPV p16 expression status was positive in 29/34(85.3%) patients. The 4-year progression-free survival and overall survival in HPVpositive patients were 78% and 92%, respectively.Acute grade 3 skin and gastrointestinal toxicities were reported in 5% and 7.3% of patients, respectively;patients' compliance to the treatment was good due to a low occurrence of severe acute toxicity, although treatment interruptions due to toxicity were required in 7.3% of patients. At 6 mo from end of treatment,36/40(90%) patients obtained complete response;during follow-up, 5(13.8%) patients presented with disease progression(local or systemic).CONCLUSION: In our experience, intensified SIBIMRT with chemotherapy is very feasible in clinical practice, with excellent results in terms of overall survival and local control. | Liliana Belgioia Stefano Vagge Dario Agnese Stefania Garelli Roberto Murialdo Giuseppe Fornarini Silvana Chiara Fabio Gallo Almalina Bacigalupo Renzo Corvò | 2015 | World Journal of Gastroenterology2015，21，37： | 2 |
| 18 | Non-cirrhotic portal hypertension with large regenerative nodules: A diagnostic challenge显示文摘Non-cirrhotic portal hypertension is a poorly understood condition characterized by portal hypertension in the absence of conventional hepatic cirrhosis and described in association with blood coagulation disorders, myeloproliferative and immunological diseases and with exposure to toxic drugs. Very recently, precise classification criteria have been proposed in order to define four distinct subcategories. The present case highlights how the clinical presentation, the confounding results from imaging studies, and the difficulties in the histological evaluation often render cases of non-cirrhotic portal hypertension a real diagnostic challenge. It also underscores the classification problems which can be faced once this diagnosis is performed. Indeed, the different subcategories proposed result from the prevalent subtypes in a spectrum of hepatic regenerative responses to a variety of injuries determining microcirculatory dis-turbances. More flexibility in classification should derive from this etiopathogenic background. | Umberto Vespasiani Gentilucci Paolo Gallo Giuseppe Perrone Riccardo Del Vescovo Giovanni Galati Sandro Spataro Chiara Mazzarelli Adriano Pellicelli Antonella Afeltra Antonio Picardi | 2011 | World Journal of Gastroenterology2011，17，20： | 2 |
| 19 | Identification of influential spreaders in complex networks显示文摘 | Kitsak Maksim Gallos Lazaros K Havlin Shlomo Liljeros Fredrik Muchnik Lev Stanley H Eugene Makse Hernán A | 2010 | Nature Physics2010，，11： | 2 |
| 20 | Review article: biofilm formation by H elicobacter pylori as a target for eradication of resistant infection显示文摘 | G. Cammarota M. Sanguinetti A. Gallo B. Posteraro | 2012 | Aliment Pharmacol Ther2012，，3： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员